Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ahn, Hee Kyung | - |
dc.contributor.author | Kim, Seok Jin | - |
dc.contributor.author | Yun, Jina | - |
dc.contributor.author | Yi, Jun Ho | - |
dc.contributor.author | Kim, Jung-Hoon | - |
dc.contributor.author | Won, Young-Woong | - |
dc.contributor.author | Kim, Kihyun | - |
dc.contributor.author | Ko, Young Hyeh | - |
dc.contributor.author | Kim, Won Seog | - |
dc.date.accessioned | 2022-12-20T18:23:22Z | - |
dc.date.available | 2022-12-20T18:23:22Z | - |
dc.date.created | 2022-08-26 | - |
dc.date.issued | 2010-04 | - |
dc.identifier.issn | 0925-5710 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/175216 | - |
dc.description.abstract | The addition of rituximab to cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) improved the outcome of patients with diffuse large B-cell lymphoma (DLBCL). However, the impact of rituximab (R-CHOP) is still not determined in primary mediastinal large B-cell lymphoma (PMBCL), a subtype of DLBCL, especially in Asian patients. Thus, we analyzed the treatment outcome of PMBCL patients (n = 21) treated with R-CHOP and compared it with the historical group treated with CHOP (n = 14). The rate of complete response for R-CHOP was higher than that of CHOP (17/21, 81.0% vs. 8/14, 57.2%), although the difference was not statistically significant (P = 0.151). The number of patients with disease progression or relapse was higher in the CHOP group (6/14, 42.9%) than the R-CHOP group (2/21, 9.5%). Thus, patients treated with R-CHOP had higher 2-year progression-free survival (79.0%) than those treated with CHOP (50.0%, P = 0.043). Although the 2-year overall survival of the R-CHOP was also superior to that of the CHOP group (82.7% vs. 57.1%), this survival benefit did not reach statistical significance (P = 0.081). In conclusion, our comparison suggests that R-CHOP may increase response and reduce relapse resulting in prolongation of progression-free survival of patients with PMBCL. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER TOKYO | - |
dc.title | Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Won, Young-Woong | - |
dc.identifier.doi | 10.1007/s12185-010-0536-6 | - |
dc.identifier.scopusid | 2-s2.0-77950916558 | - |
dc.identifier.wosid | 000276264800012 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF HEMATOLOGY, v.91, no.3, pp.456 - 463 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF HEMATOLOGY | - |
dc.citation.title | INTERNATIONAL JOURNAL OF HEMATOLOGY | - |
dc.citation.volume | 91 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 456 | - |
dc.citation.endPage | 463 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordPlus | CHOP-LIKE CHEMOTHERAPY | - |
dc.subject.keywordPlus | NON-HODGKINS-LYMPHOMAS | - |
dc.subject.keywordPlus | SINGLE-INSTITUTION | - |
dc.subject.keywordPlus | YOUNG-PATIENTS | - |
dc.subject.keywordPlus | EXPERIENCE | - |
dc.subject.keywordPlus | SCLEROSIS | - |
dc.subject.keywordPlus | RADIOTHERAPY | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | RADIATION | - |
dc.subject.keywordAuthor | Mediastinal large B-cell lymphoma | - |
dc.subject.keywordAuthor | Prognosis | - |
dc.subject.keywordAuthor | Rituximab | - |
dc.identifier.url | https://link.springer.com/article/10.1007/s12185-010-0536-6 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.